Brokerages Set Evommune, Inc. (NYSE:EVMN) Price Target at $39.33

Evommune, Inc. (NYSE:EVMN) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $39.3333.

EVMN has been the topic of several analyst reports. Cantor Fitzgerald started coverage on shares of Evommune in a research report on Monday, December 1st. They set an “overweight” rating on the stock. Leerink Partners initiated coverage on shares of Evommune in a research note on Monday, December 1st. They set an “outperform” rating and a $42.00 target price on the stock. Zacks Research upgraded Evommune to a “hold” rating in a research note on Tuesday, December 2nd. Leerink Partnrs upgraded Evommune to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Morgan Stanley assumed coverage on Evommune in a report on Monday, December 1st. They issued an “overweight” rating and a $36.00 price objective on the stock.

Evommune Stock Performance

Evommune stock opened at $17.09 on Friday. Evommune has a 52 week low of $13.89 and a 52 week high of $24.03.

Evommune (NYSE:EVMN) last released its quarterly earnings data on Thursday, December 11th. The company reported ($8.07) EPS for the quarter, missing the consensus estimate of ($6.58) by ($1.49). The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.